$546.46 Million in Sales Expected for Amneal Pharmaceuticals, Inc. (NYSE:AMRX) This Quarter

Equities research analysts expect Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to announce sales of $546.46 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Amneal Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $537.42 million and the highest estimate coming in at $556.90 million. Amneal Pharmaceuticals reported sales of $519.29 million during the same quarter last year, which indicates a positive year over year growth rate of 5.2%. The firm is scheduled to report its next quarterly earnings results on Friday, November 5th.

On average, analysts expect that Amneal Pharmaceuticals will report full year sales of $2.13 billion for the current year, with estimates ranging from $2.12 billion to $2.15 billion. For the next year, analysts forecast that the firm will post sales of $2.19 billion, with estimates ranging from $2.16 billion to $2.21 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Sunday, August 8th. The company reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.07. Amneal Pharmaceuticals had a return on equity of 58.68% and a net margin of 0.45%. The business had revenue of $535.10 million for the quarter, compared to the consensus estimate of $523.26 million. During the same quarter in the previous year, the business earned $0.13 EPS. The company’s quarterly revenue was up 15.1% compared to the same quarter last year.

Separately, Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $7.17.

NYSE AMRX traded down $0.15 during mid-day trading on Tuesday, hitting $5.54. The stock had a trading volume of 482,081 shares, compared to its average volume of 1,295,117. The firm’s 50 day moving average is $5.29 and its 200 day moving average is $5.37. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of 92.33, a PEG ratio of 0.25 and a beta of 1.22. The company has a debt-to-equity ratio of 7.07, a current ratio of 2.32 and a quick ratio of 1.55. Amneal Pharmaceuticals has a twelve month low of $3.90 and a twelve month high of $7.45.

Hedge funds have recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Amneal Pharmaceuticals in the third quarter valued at $29,000. Strs Ohio increased its holdings in Amneal Pharmaceuticals by 2.3% in the 3rd quarter. Strs Ohio now owns 159,500 shares of the company’s stock valued at $851,000 after purchasing an additional 3,600 shares in the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Amneal Pharmaceuticals by 10.9% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 872,516 shares of the company’s stock worth $4,659,000 after acquiring an additional 85,700 shares during the period. Kestra Advisory Services LLC purchased a new position in Amneal Pharmaceuticals in the 3rd quarter worth approximately $144,000. Finally, Wedge Capital Management L L P NC boosted its holdings in Amneal Pharmaceuticals by 23.9% in the 3rd quarter. Wedge Capital Management L L P NC now owns 23,050 shares of the company’s stock worth $123,000 after acquiring an additional 4,448 shares during the period. Institutional investors and hedge funds own 32.91% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals.

Recommended Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.